Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Nikolas Herold. (2021) Pharmacological strategies to overcome treatment resistance in acute myeloid leukemia: increasing leukemic drug exposure by targeting the resistance factor SAMHD1 and the toxicity factor Top2β. Expert Opinion on Drug Discovery 16:1, pages 7-11.
Read now
Read now
Ming-Zhu Song, Yan-Mei Mao, Jun Wu, Hai-Feng Pan & Qian-Ling Ye. (2020) Increased circulating basic fibroblast growth factor levels in acute myeloid leukemia: a meta-analysis. Hematology 25:1, pages 186-193.
Read now
Read now
Anqi Zhou, Qi Han, Huihui Song, Jie Zi, Jinlong Ma & Zheng Ge. (2019) Efficacy and toxicity of cladribine for the treatment of refractory acute myeloid leukemia: a meta-analysis. Drug Design, Development and Therapy 13, pages 1867-1878.
Read now
Read now
Xielan Zhao, Juan Liu, Minyuan Peng, Jing Liu & Fangping Chen. (2013) BMP4 is Involved in the Chemoresistance of Myeloid Leukemia Cells Through Regulating Autophagy–Apoptosis Balance. Cancer Investigation 31:8, pages 555-562.
Read now
Read now
Articles from other publishers (23)
Susu Cao, Qianshan TaoJia WangQing ZhangYi Dong. (2023) Cladribine, cytarabine, and filgrastim based regimen in relapsed or refractory acute myeloid leukemia: A systematic review and meta-analysis. Medicine 102:44, pages e34949.
Crossref
Crossref
Tianzhen Hu, Chengyun Pan, Tianzhuo Zhang, Ming Ni, Weili Wang, Siyu Zhang, Ying Chen, Jishi Wang & Qin Fang. (2022) Nrf2 overexpression increases the resistance of acute myeloid leukemia to cytarabine by inhibiting replication factor C4. Cancer Gene Therapy 29:11, pages 1773-1790.
Crossref
Crossref
Bradley Stockard, Neha Bhise, Miyoung Shin, Joy Guingab-Cagmat, Timothy J. Garrett, Stanley Pounds & Jatinder K. Lamba. (2021) Cellular Metabolomics Profiles Associated With Drug Chemosensitivity in AML. Frontiers in Oncology 11.
Crossref
Crossref
Amanda L. Olson, Rima M. Saliba, Betul Oran, Julianne Chen, Amin Alousi, Sairah Ahmed, Qaiser Bashir, Stefan O. Ciurea, Chitra Hosing, Jin Seon Im, Partow Kebriaei, Issa F. Khouri, Rohtesh Mehta, Yago Nieto, Simrit Parmar, Katy Rezvani, Nina Shah, Elizabeth Shpall, Samer A. Srour, Muzaffar Qazilbash, Borje S. Andersson, Richard Champlin & Uday R. Popat. (2021) Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematologica 144:1, pages 74-81.
Crossref
Crossref
Peipei Ye, Renzhi Pei, Jie Jin, Jie Sun, Kongfei Li, Junjie Cao, Dandan Zhou & Ying Lu. (2019) Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation. Annals of Hematology 98:9, pages 2073-2080.
Crossref
Crossref
Abu-Sayeef Mirza, Jeffrey E. Lancet, Kendra Sweet, Eric Padron, Javier Pinilla-Ibarz, Lisa Nardelli, Christopher Cubitt, Alan F. List & Rami S. Komrokji. (2017) A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 17:12, pages 902-907.
Crossref
Crossref
Wenjuan Yang & Yunxiao Xu. (2013) Clinical significance of Treg cell frequency in acute myeloid leukemia. International Journal of Hematology 98:5, pages 558-562.
Crossref
Crossref
Wei-Ping Zhang, Dan Yang, Xian-Min Song, Xiong Ni, Jie Chen, Li Chen, Jian-min Yang, Hong Zhou, Hui Cheng, Bao-hai Liu, Hong-Mei Li & Jian-Min Wang. (2013) Allogeneic Peripheral Blood Stem Cell Transplantation is a Promising and Safe Choice for the Treatment of Refractory/Relapsed Acute Myelogenous Leukemia, Even with a Higher Leukemia Burden. Biology of Blood and Marrow Transplantation 19:4, pages 653-660.
Crossref
Crossref
Y Wang, D-H Liu, L-P Xu, K-Y Liu, H Chen, X-H Zhang, Y-H Chen, W Han, F-R Wang, J-Z Wang, C-H Yan & X-J Huang. (2011) Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis. Bone Marrow Transplantation 47:8, pages 1099-1104.
Crossref
Crossref
Yu Wang, Dai‐Hong Liu, Zhi‐Ping Fan, Jing Sun, Xiao‐Jin Wu, Xiao Ma, Lan‐Ping Xu, Kai‐Yan Liu, Qi‐Fa Liu, De‐Pei Wu & Xiao‐Jun Huang. (2012)
Prevention of relapse using
DLI
can increase survival following
HLA
‐identical transplantation in patients with advanced‐stage acute leukemia: a multi‐center study
. Clinical Transplantation 26:4, pages 635-643.
Crossref
Crossref
Ki-Seong Eom, Woo-Sung Min, Hee-Je Kim, Byung-Sik Cho, Su-Mi Choi, Dong-Gun Lee, Seok Lee, Chang-Ki Min, Yoo-Jin Kim, Seok-Goo Cho, Jong-Wook Lee & Chun-Choo Kim. (2010) FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia. Medical Oncology 28:S1, pages 462-470.
Crossref
Crossref
Anjali S. Advani, Ramon Tiu, Yogen Saunthararajah, Jaroslaw Maciejewski, Edward A. Copelan, Ronald Sobecks, Mikkael A. Sekeres, Jennifer Bates, Mary Lynn Rush, Barbara Tripp, August Salvado, Elysa Noon, Matthew Howard, Tao Jin, Eric Hsi, Merrill J. Egorin, Kathleen Lim, Claudiu V. Cotta, Courtney Price & Matt Kalaycio. (2010) A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia. Leukemia Research 34:12, pages 1622-1626.
Crossref
Crossref
Marco Montillo, Francesca Ricci, Alessandra Tedeschi, Anna Maria Cafro, Anna Maria Nosari, Michele Nichelatti, Laura Marbello & Enrica Morra. (2009) Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia. Leukemia Research 33:8, pages 1072-1078.
Crossref
Crossref
Sung-Sook Lee, Je-Hwan Lee, Jung-Hee Lee, Dae-Young Kim, Se Hyung Kim, Sung-nam Lim, Young-Shin Lee, Miee Seol, Seong-Gil Ryu, Young-Ah Kang, Seongsoo Jang, Chan-Jeoung Park, Hyun-Sook Chi, Sung-Cheol Yun & Kyoo-Hyung Lee. (2009) Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia. Leukemia Research 33:4, pages 511-517.
Crossref
Crossref
Tadeusz Robak & Agnieszka Wierzbowska. (2009) Current and emerging therapies for acute myeloid leukemia. Clinical Therapeutics 31, pages 2349-2370.
Crossref
Crossref
Xiao-Jun Huang, Yu Wang, Dai-Hong Liu, Lan-Ping Xu, Huan Chen, Yu-Hong Chen, Wei Han, Hong-Xia Shi & Kai-Yan Liu. (2008) Modified Donor Lymphocyte Infusion (DLI) for the Prophylaxis of Leukemia Relapse after Hematopoietic Stem Cell Transplantation in Patients with Advanced Leukemia—Feasibility and Safety Study. Journal of Clinical Immunology 28:4, pages 390-397.
Crossref
Crossref
Xiao-Jun Huang, Dai-Hong Liu, Kai-Yan Liu, Lan-Ping Xu, Yu-Hong Chen, Yu Wang, Wei Han & Huan Chen. (2008) Modified Donor Lymphocyte Infusion after HLA-Mismatched/Haploidentical T Cell-replete Hematopoietic Stem Cell Transplantation for Prophylaxis of Relapse of Leukemia in Patients with Advanced Leukemia. Journal of Clinical Immunology 28:3, pages 276-283.
Crossref
Crossref
Anthony R Mato, Alicia Morgans & Selina M Luger. (2008) Novel strategies for relapsed and refractory acute myeloid leukemia. Current Opinion in Hematology 15:2, pages 108-114.
Crossref
Crossref
Agnieszka Wierzbowska, Tadeusz Robak, Agnieszka Pluta, Ewa Wawrzyniak, Barbara Cebula, Jerzy Hołowiecki, Sławomira Kyrcz-Krzemień, Sebastian Grosicki, Sebastian Giebel, Aleksander B. Skotnicki, Beata Piątkowska-Jakubas, Kazimierz Kuliczkowski, Marek Kiełbiński, Krystyna Zawilska, Janusz Kłoczko & Agata Wrzesień-Kuś. (2007) Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukem. European Journal of Haematology 80:2, pages 115-126.
Crossref
Crossref
Je-Hwan Lee, Seong-Jun Choi, Jung-Hee Lee, Young-Shin Lee, Miee Seol, Seong-Gil Ryu, Seongsoo Jang, Chan-Jeoung Park, Hyun-Sook Chi, Jung-Shin Lee, Woo-Kun Kim & Kyoo-Hyung Lee. (2006) Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia. Leukemia Research 30:2, pages 204-210.
Crossref
Crossref
A. Wrzesień-Kuś, T. Robak, A. Wierzbowska, E. Lech-Marańda, A. Pluta, E. Wawrzyniak, A. Krawczyńska, K. Kuliczkowski, G. Mazur, M. Kiebiński, A. Dmoszyńska, M. Wach, A. Hellmann, W. Baran, J. Hołowiecki, S. Kyrcz-Krzemień & S. Grosicki. (2005) A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Annals of Hematology 84:9, pages 557-564.
Crossref
Crossref
A. Wrzesień-Kuś, T. Robak, E. Lech-Marańda, A. Wierzbowska, A. Dmoszyńska, M. Kowal, J. Hołowiecki, S. Kyrcz-Krzemień, S. Grosicki, S. Maj, A. Hellmann, A. Skotnicki, W. Je˛drzejczak & K. Kuliczkowski. (2003) A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG). European Journal of Haematology 71:3, pages 155-162.
Crossref
Crossref
. (2002) Current Awareness in Hematological Oncology. Hematological Oncology 20:4, pages 189-196.
Crossref
Crossref